5-[(2-Methylpropan-2-yl)oxycarbonyl-[2-[3-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethoxy]phenyl]pyrimidin-4-yl]amino]indazole-1-carboxylic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-[(2-Methylpropan-2-yl)oxycarbonyl-[2-[3-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethoxy]phenyl]pyrimidin-4-yl]amino]indazole-1-carboxylic acid
• 英文别名: 5-[(2-methylpropan-2-yl)oxycarbonyl-[2-[3-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethoxy]phenyl]pyrimidin-4-yl]amino]indazole-1-carboxylic acid
• 化学式: C₂₉H₃₁N₅O₇
• 分子量: 561.6
• InChiKey: UGKLUTPXTTYTGP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  41
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  146
• 氢给体数：
  1
• 氢受体数：
  10

文献信息

• [EN] TREATMENT OF GVHD<br/>[FR] TRAITEMENT DE LA RÉACTION DU GREFFON CONTRE L'HÔTE
  申请人：KADMON CORP LLC

  公开号：WO2015157556A1

  公开（公告）日：2015-10-15

  The invention relates to treatment of graft versus host disease (GVHD) using compounds that inhibit ROCK2. In preferred aspects, the present invention provides methods for the treatment of GVHD, including chronic GVHD ( cGVHD) using compounds having the formulae l-XXV, as set forth herein.

  这项发明涉及使用抑制ROCK2的化合物治疗移植物抗宿主病（GVHD）。在首选方面，本发明提供了治疗GVHD的方法，包括慢性GVHD（cGVHD），使用具有以下公式的化合物l-XXV。
• RHO KINASE INHIBITORS
  申请人：Kadmon Corporation, LLC

  公开号：EP2903618A2

  公开（公告）日：2015-08-12
• TREATMENT OF OCULAR DISORDERS
  申请人：Kadmon Corporation, LLC

  公开号：EP2903645A2

  公开（公告）日：2015-08-12
• [EN] RHO KINASE INHIBITORS<br/>[FR] INHIBITEURS DE RHO KINASE
  申请人：KADMON CORP LLC

  公开号：WO2014055996A2

  公开（公告）日：2014-04-10

  The invention relates to inhibitors of ROCKl and/or ROCK2. Also provided are methods of treating diseases and disorders involving inhibiting ROCKl and/or ROCK2.
• [EN] TREATMENT OF OCULAR DISORDERS<br/>[FR] TRAITEMENT DE TROUBLES OCULAIRES
  申请人：KADMON CORP LLC

  公开号：WO2014055999A2

  公开（公告）日：2014-04-10

  The invention provides methods of treatment of ocular disorders, including ocular disease with an angiogenic component. In certain embodiments, the treatment comprises administration of a ROCK2 inhibitor and an angiogenesis inhibitor. In certain embodiments, the ROCK2 inhibitor is ROCK2 selective. In certain embodiments, the angiogenesis inhibitor is a VEGF antagonist, for example, and VEGFR2 antibody.